2. NF-κB Stem Cell/Wnt MAPK/ERK Pathway Immunology/Inflammation
  3. NF-κB ERK JNK p38 MAPK Interleukin Related
  4. CLP-d2

CLP-d2 is a multi-target anti-inflammatory agent, osteoclastogenesis inhibitor and immunomodulator with superior pharmacokinetic properties to Daptomycin (HY-B0108) and good safety profiles. CLP-d2 inhibits the NF-κB and MAPK signaling pathways by reducing the expression levels of c-Fos and NFATc1, and decreasing the phosphorylation levels of IκBα, p65, ERK and JNK, thereby reducing the secretion of pro-inflammatory cytokines such as IL-6, TNF-α and IL-1β to exert anti-inflammatory activity. CLP-d2 inhibits intra-articular osteoclastogenesis in mice, alleviates bone erosion and joint swelling, reduces synovial hyperplasia and inflammatory cell infiltration, and decreases serum rheumatoid factor (RF) levels. CLP-d2 is applicable to related research on rheumatoid arthritis.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

CLP-d2

CLP-d2 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

CLP-d2 Related Antibodies

Top Publications Citing Use of Products

View All NF-κB Isoform Specific Products:

View All Isoforms
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

View All ERK Isoform Specific Products:

View All Isoforms
ERK ERK1 ERK2 ERK5 ERK8

View All JNK Isoform Specific Products:

View All Isoforms
JNK1 JNK2 JNK3 JNK

View All p38 MAPK Isoform Specific Products:

View All Isoforms
p38 MAPK Akt1 p38α p38β MAPK13 p38δ p38γ

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

CLP-d2 is a multi-target anti-inflammatory agent, osteoclastogenesis inhibitor and immunomodulator with superior pharmacokinetic properties to Daptomycin (HY-B0108) and good safety profiles. CLP-d2 inhibits the NF-κB and MAPK signaling pathways by reducing the expression levels of c-Fos and NFATc1, and decreasing the phosphorylation levels of IκBα, p65, ERK and JNK, thereby reducing the secretion of pro-inflammatory cytokines such as IL-6, TNF-α and IL-1β to exert anti-inflammatory activity. CLP-d2 inhibits intra-articular osteoclastogenesis in mice, alleviates bone erosion and joint swelling, reduces synovial hyperplasia and inflammatory cell infiltration, and decreases serum rheumatoid factor (RF) levels. CLP-d2 is applicable to related research on rheumatoid arthritis[1].

IC50 & Target

p65

 

IL-6

 

IL-1β

 

I-kappaBalpha

 

In Vitro

CLP-d2 (10 μg/mL; 24 h) potently uppresses the secretion of pro-inflammatory cytokines and their transcription levels in RAW264.7 cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

CLP-d2 Related Antibodies

RT-PCR[1]

Cell Line: RAW264.7 cells
Concentration: 10 μg/mL
Incubation Time: 24 h
Result: Inhibits secretion and gene transcription of IL-6, TNF-α, and IL-1β in LPS-stimulated RAW264.7 cells, with the greatest inhibition of IL-6 (93.7% reduction in gene level)
In Vivo

CLP-d2 (10 mg/kg; i.v.; every 2 days; 40 days) exerts anti-rheumatoid arthritis effects in collagen-induced arthritis mice, with a 45.9% reduction in arthritis score and significant inhibition of inflammatory pathways and joint destruction[1].
CLP-d2 (10 mg/kg; i.v.; single dose) exhibits favorable pharmacokinetic parameters in Balb/c mice, including a larger AUC0-t and longer T1/2 compared to daptomycin[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: DBA/1J male mice (6−7 weeks)[1]
Dosage: 10 mg/kg
Administration: i.v.; every 2 days; 40 days
Result: Increased body weight by 12% compared to the CIA group; reduced arthritis score by 45.9% compared to the CIA group; reduced serum RF levels by 46.0%, serum IL-6 levels by 54.2%, serum TNF-α levels by 25.9%, and serum IL-1β levels by 42.6% compared to the CIA group; reduced joint histopathological scores by 70.4% compared to the CIA group; reduced IL-6 IHC scores by 46.4%, IL-1β IHC scores by 59.2%, and TNF-α IHC scores by 49.3% compared to the CIA group; reduced p-IκBα IHC scores by 59.3%, p-p65 IHC scores by 58.6%, p-ERK IHC scores by 60.9%, p-JNK IHC scores by 58.6%, c-Fos IHC scores by 59.1%, and NFATc1 IHC scores by 66.6% compared to the CIA group; reduced bone erosion and paw swelling; inhibited p65 nuclear translocation and osteoclast generation in joints.
Animal Model: Balb/c mice[1]
Dosage: 10 mg/kg
Administration: i.v.; single dose
Result: Reported AUC(0-t) of 255.53 mg/L*h, T1/2 of 1.43 h, Tmax of 0.5 h, VZ of 0.08 L/kg, CLZ of 0.04 L/h/kg, and Cmax of 73.93 mg/L.
Molecular Weight

1725.76

Formula

C78H104N18O27
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

CLP-d2 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

CLP-d2NF-κBERKJNKp38 MAPKInterleukin RelatedNuclear factor-κBNuclear factor-kappaBExtracellular signal regulated kinasesc-Jun N-terminal kinaseILosteoclastogenesiscollagen-induced arthritis miceMAPK signaling pathwayrheumatoid arthritisRAW264.7 cellsNF-κB signaling pathwaypro-inflammatory cytokinesNFATc1Balb/c micec-FosInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
CLP-d2
Cat. No.:
HY-P11617
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.